Research programme: PFKFB3 inhibitors - Advanced Cancer Therapeutics

Drug Profile

Research programme: PFKFB3 inhibitors - Advanced Cancer Therapeutics

Alternative Names: 3PO; PFKFB3 inhibitors - Advanced Cancer Therapeutics

Latest Information Update: 12 Oct 2012

Price : $50

At a glance

  • Originator University of Louisville
  • Developer Advanced Cancer Therapeutics
  • Class Small molecules
  • Mechanism of Action PFKFB3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Glioblastoma

Most Recent Events

  • 11 Oct 2012 Advanced Cancer Therapeutics receives SBIR grant from the National Cancer Institute for development of a PFKFB3 inhibitor in Glioblastoma
  • 11 Oct 2012 Preclinical trials in Glioblastoma in USA (unspecified route)
  • 03 Apr 2012 Preclinical development is ongoing US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top